Society of Nuclear Medicine and Molecular Imaging (SNMMI)’s Post

When the FDA approved ioflupane-123, the radiotracer that helps diagnose Parkinson’s Disease, 99% of clinical trial participants were white. Racial disparities in healthcare are an unfortunate reality, but this study, published in the Journal of Nuclear Medicine Technology, takes a first look at the effect of ethnicity on dopamine transporter binding capacity. Read more about the effect of demographic variables on the prevalence of neurodegenerative diseases, including Parkinson’s. Read the full article here: https://lnkd.in/eTRaU9Tr #nuclearmedicine #nucmedtech #healthcare

To view or add a comment, sign in

Explore topics